Exclusive: Strand lays off 18% of staff as its first mRNA therapies head into the clinic
26 Jan 2024
mRNA
Less than a week after announcing that regulators have greenlit the first tests of its tumor-busting mRNA therapy, Strand Therapeutics has laid off roughly 18% of its employees, Endpoints News has learned.
Strand was founded in 2017 based on research of MIT synthetic biologists who figured out how to program on and off switches into mRNA. Those genetic circuits, as they’re called, offered a way to potentially improve the safety and effectiveness of drugs based on the genetic molecules.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.